“Patients who were on the course of treatment survived for 19.3 months compared to 16.5 months for the control group.

The long tail is more interesting where 13 percent of those treated survived for five years, while only 5.7 percent of the control group did. 331 patients were enrolled in the trial.

According to the results, there is still a long way to go.”

I’m stoked to see treatments make it into the clinical trials stage. Not that proof of concepts are meaningless, but there’s a gulf between proof of concept and the rubber meets the road stage of clinical trials. Hope this goes well!